A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES)

To evaluate the efficacy of QTI571 compared to placebo as measured by the change in 6- minute walk distance (6MWD) from baseline to 24-weeks

Kusajili – Centralise les essais cliniques mondiaux